DiagnaMed Unveils First Commercial AI Product For Healthcare Industry, FormGPT
FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.
DiagnaMed Holdings (CSE: DMED) has launched its first commercial product under its initiative to bring artificial intelligence to the healthcare industry. The initiative is currently focused on using AI to improve patient outcomes, operational workflow, and efficiency within the industry.
“With the recent advances in generative AI following the release of ChatGPT and GPT-4, and our experience with applying AI for brain health, we see a significant opportunity to launch niche AI healthcare solutions that leverage our core competencies and complement CERVAI™, our generative AI brain health platform,” commented CEO Fabio Chianelli.
The first product under that initiative is referred to as FormGPT.io. The tech is said to be a generative AI data collection and analysis solution, enabling healthcare providers to create customized forms and surveys via the use of ChatGPT. The program is said to assist in collecting relevant patient data, obtaining pre and post-visit treatment and feedback, monitor patient progress, and analyze results to assist in decision making.
FormGPT, which has launched a minimum viable product version that is available to the public for a free seven day trial, is intended to enable professionals and clinical researchers to develop forms and surveys that improve workflow and research objectives. The tech is also expected to increase user services, patient outcomes, and engagement.
The new product is said to have been created based on DiagnaMed’s own experience within the industry, with the new product featuring its generative AI brain health platform, CERVAI.
The development follows the company in February entering a licensing deal with the University of Miami for the development and commercialization of intellectual property for a novel brain health platform.
The licensing agreement will see the integration of a novel brain health platform that has been designed for the evaluation, diagnosis and monitoring of brain health into that of CERVAI. The tech was developed by James Gavin, whom is Professor of Neurology and Psychiatry and Behavioral Sciences at the Miller School of Medicine at the University of Miami, and also the founding director of the Comprehensive Center for Brain Health at the U of M Health System.
DiagnaMed Holdings last traded at $0.04 on the CSE.
FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
